verified SJR 0,394 · Q3 • database Scopus / SJR indexed

United Arab Emirates · Bentham Science Publishers

workspace_premium Q3 — Drug Discovery lock Subscription

Current Drug Discovery Technologies

Current Drug Discovery Technologies is a journal indexed in SJR in Drug Discovery with an H index of 52. It has an SJR impact factor of 0,394 and it has a best quartile of Q3. It is published in English. It has an SJR impact factor of 0,394.

ISSN: 1570-1638

Publisher: Bentham Science Publishers

Category: Drug Discovery

Indexation: verifiedScopus / SJR

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

0,394 Q3

H-index 52

Acceptance rate pie_chart

32%

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Subscription

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR

SJR Impact

0,394

H-index

Docs (year)

Docs 3y

157

Total refs

3125

Cites 3y

303

Citable 3y

153

Cites/Doc 2y

1.72

Ref/Doc

61.27

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

CoMFA, CoMSIA and HQSAR Analysis of 3-aryl-3-ethoxypropanoic Acid Derivatives as GPR40 Modulators

Use of Compound Chinese Medicine in the Treatment of Lung Cancer

Design, Synthesis and Pharmacological Evalution of 1,3,4-Oxadiazole Derivatives as Collapsin Response Mediator Protein 1 (CRMP 1) Inhibitors

Design, Synthesis and Anticancer Activity of Site Specific Short Chain Cationic Peptide

Design and Synthesis of New N1 and C3-Substituted 4-Fluoroindolic Melatoninergics

Current Treatment Strategies for Non-Alcoholic Fatty Liver Disease (NAFLD)

Current Treatment of Psoriasis with Biologics

Current Treatment of Autoimmune Blistering Diseases

Current Discovery Progress of Some Emerging Anti-infective Chalcones: Highlights from 2016 to 2017

Current Concepts and Future Directions in Radioimmunotherapy

Cubosomes as Targeted Drug Delivery Systems - A Biopharmaceutical Approach

Crohns Targeted Therapy: Myth or Real Goal?

SHOW MORE ARTICLES

Core-in-Cup Tablet Design of Metoprolol Succinate and its Evaluation for Controlled Release

A New Scoring Function for Molecular Docking Based on AutoDock and AutoDock Vina

Combinatorial Chemistry and Fragment Screening - Two Unlike Siblings?

Chemoinformatics Approaches for Traditional Chinese Medicine Research and Case Application in Anticancer Drug Discovery

Biologics as Treatment for Systemic Lupus: Great Efforts, Sobering Results, New Challenges

Aripiprazole: An FDA Approved Bioactive Compound to Treat Schizophrenia- A Mini Review

Application of Graph-Based Analysis of Genomic Sequence Context for Characterization of Drug Targets

Antimalarial Drugs and their Useful Therapeutic Lives: Rational Drug Design Lessons from Pleiotropic Action of Quinolines and Artemisinins

Antibody Discovery: Sourcing of Monoclonal Antibody Variable Domains

Anti-Inflammatory and Anti-Oxidant Activity of a New Class of Phenyl- Pyrazolone Derivatives

Align: a C++ Class Library and Web Server for Rapid Sequence Alignment Prototyping

Advanced Glycation End Products (AGEs) and their Receptor (RAGE) System in Diabetic Retinopathy

FAQs

Current Drug Discovery Technologies has an SJR of 0,394 (best quartile Q3) in the CountryOfPapers database.

Immediate OA APC is not available (NPD).

The acceptance rate recorded for Current Drug Discovery Technologies is 32%.

Current Drug Discovery Technologies

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Current Drug Discovery Technologies?

What is the APC / publication cost?

What is the acceptance rate?